The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer

By Kim Seung  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1277-1285

Humana Press, Inc

Access to resources Recommend Favorite

Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy

By          

Oncology Letters, Vol. 4, Iss. 5, 2012-01 ,pp. : 905-909

Spandidos Publications

Access to resources Recommend Favorite

Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor

By Tetzlaff Eric   Ajani Jaffer  

International Journal of Gastrointestinal Cancer, Vol. 36, Iss. 1, 2005-08 ,pp. : 55-58

Humana Press, Inc

Access to resources Recommend Favorite

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

By Petrioli Roberto   Licchetta Antonella   Roviello Giandomenico   Pascucci Alessandra   Francini Edoardo   Bargagli Gianluca   Conca Raffaele   Miano Salvatora Tindara   Marzocca Giuseppe   Francini Guido    

Cancer Investigation, Vol. 30, Iss. 1, 2012-01 ,pp. : 65-71

Informa Healthcare

Access to resources Recommend Favorite

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite